Ocular Tolerance, Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1.0, 1.5% in 48 Healthy Volunteers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00357292|
Recruitment Status : Completed
First Posted : July 27, 2006
Last Update Posted : July 27, 2006
|Condition or disease||Intervention/treatment||Phase|
|Eye Infections, Bacterial||Drug: Azithromycin (T1225)||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Official Title:||Comparison of the Ocular Tolerance, the Safety and the Ocular Pharmacokinetics After One Drop of Three Different Concentrations of T1225 (0.5% - 1.0% - 1.5%) in 48 Healthy Volunteers|
|Study Start Date :||March 2002|
|Study Completion Date :||April 2002|
- Ocular subjective symptoms
- Ocular objective symptoms
- Ocular pharmacokinetic.
- Ocular and systemic adverse events.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00357292
|Principal Investigator:||Khalid TABBARA, Professor||The Eye Center, Riyadh (Saudi Arabia)|